NanoSphere Expert Interviews – Insights from Leaders in Nanomedicine

Endosomal escape in nanomedicines isn’t a novel problem, it’s just a new chapter of our cellular defence against invading material. Studying and learning from natural mechanisms will likely be key to future breakthroughs.

— Michael Munson, PhD – Associate Principal Scientist Respiratory & Immunology, AstraZeneca

Check the full interview here.

Juliane Nguyen, PhD, FCRS, FAAPS, FAIMBE (she/her) Professor and Vice Chair Director of Graduate Admissions - DPMP Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy University of North Carolina at Chapel Hill

Paola LucianiFull Professor of Pharmaceutical Technology at the University of Bern

Giovanna LolloAssociate Professor of Pharmaceutical Technology, University Claude Bernard Lyon 1

Mohammad Azhar AzizFounder Director, Cancer Nanomedicine Consortium Former Director, Interdisciplinary Nanotechnology Center, ZHCET, Aligarh Muslim University

Yvan DevauxHead of Cardiovascular Research Unit at the Luxembourg Institute of Health

Eva HemmrichRegulatory Science Lead, The University of Basel

Álvaro SomozaSenior Researcher at IMDEA Nanociencia (Madrid, Spain) Head of the Nanobiotechnology Group.

Christian CeliaAssociate Professor of Pharmaceutical Technology, Drug Delivery and Nanomedicine

Dan PeerProfessor and Director, Laboratory of Precision nanomedicine, Tel Aviv University (TAU)

Xiuling LuProfessor of Pharmaceutics at the University of Connecticut

John RinnMarvin Caruthers Professor, University of Colorado Boulder BioFrontiers and Biochemistry

Michelle Lynn HallAssociate Vice President, Genetic Medicine, Eli Lilly

Ritam Das Technical Development Scientist 2, Genentech/ Roche

Oya TagitProf. Dr., Professor of Biointerfaces, University of Applied Sciences and Arts Northwestern Switzerland

Twan LammersProfessor of Medicine, RWTH Aachen

Sarmad HanifIndependent Researcher, Vaccines and biotherapeutics

Philipp BeckTeam Lead for Formulation Development at Ascend Advanced

Dominik WitzigmannCo-Founder & Chief Executive Officer (CEO) - NanoVation Therapeutics (NVTx)

Aditi MehtaDirector and Head of Innovation at Merck KGaA – mRNA and LNPs

David PeelerIncoming Assistant Professor, University of Oregon, Department of Bioengineering

Martin RabelGlobal Sales Specialist - Biopharma Services at Cytiva

Alessio MalfantiAssociate Professor of Pharmaceutical Technology and Advanced Drug Delivery at the Department of Pharmaceutical and Pharmacological Sciences at the University of Padova, Italy

Cesare Di NittoSenior Business Development Specialist at CATUG

Rui ZhangCo-Founder & CEO, XGen Bio

Sean BedingfieldSenior Advisor at Eli Lilly’s Genetic Medicine division

Natalia MarkovaHead of Science Pharma, Malvern Panalytical

Miffy ChengAssistant Professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia

Maria Vitoria BentleyFull Professor at the School of Pharmaceutical Sciences of Ribeirão Preto, USP

Luis BritoVP, Delivery Platform at Beam Therapeutics

Jonathan MaurerPost-doctoral researcher at the Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO)

Rein VerbekeSenior postdoc in the Ghent Research Group on Nanomedicines, Ghent University, Belgium

Maria Jose AlonsoProfessor of Pharmacy and Pharmaceutical Technology at University of Santiago de Compostela

David SchultzFormulation Scientist - Novo Nordisk

Eleni SamaridouHead of Early-stage Formulation Development & Process Design - Merck KGaA

Dženan KovačićHead of Technology Innovation - BIOptimizers

Olivia MerkelProfessor and Chair of Drug Delivery at LMU Munich